Compare Daiichi Sankyo Co., Ltd. with Similar Stocks
Dashboard
1
Company has a low Debt to Equity ratio (avg) at times
2
Healthy long term growth as Net Sales has grown by an annual rate of 13.95% and Operating profit at 16.92%
3
Flat results in Jun 25
4
With ROE of 18.22%, it has a attractive valuation with a 4.17 Price to Book Value
5
Majority shareholders : Non Institution
6
Consistent Underperformance against the benchmark over the last 3 years
Stock DNA
Pharmaceuticals & Biotechnology
JPY 6,268,406 Million (Large Cap)
23.00
NA
0.00%
-0.21
16.94%
3.79
Revenue and Profits:
Net Sales:
474,597 Million
(Quarterly Results - Jun 2025)
Net Profit:
85,500 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
3178.86%
0%
3178.86%
6 Months
3983.4%
0%
3983.4%
1 Year
4527.42%
0%
4527.42%
2 Years
6656.95%
0%
6656.95%
3 Years
12428.38%
0%
12428.38%
4 Years
12202.74%
0%
12202.74%
5 Years
14650.64%
0%
14650.64%
Daiichi Sankyo Co., Ltd. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
13.95%
EBIT Growth (5y)
16.92%
EBIT to Interest (avg)
14.00
Debt to EBITDA (avg)
0
Net Debt to Equity (avg)
-0.33
Sales to Capital Employed (avg)
0.96
Tax Ratio
16.91%
Dividend Payout Ratio
38.47%
Pledged Shares
0
Institutional Holding
0.00%
ROCE (avg)
15.44%
ROE (avg)
9.72%
Valuation key factors
Factor
Value
P/E Ratio
23
Industry P/E
Price to Book Value
4.17
EV to EBIT
20.55
EV to EBITDA
16.76
EV to Capital Employed
5.74
EV to Sales
3.30
PEG Ratio
0.46
Dividend Yield
NA
ROCE (Latest)
27.96%
ROE (Latest)
18.22%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bearish
Bearish
RSI
No Signal
Bullish
Bollinger Bands
Mildly Bearish
Mildly Bearish
Moving Averages
Bearish (Daily)
KST
Bearish
Bearish
Dow Theory
No Trend
No Trend
OBV
No Trend
No Trend
Shareholding Snapshot : Sep 2025
Shareholding Compare (%holding) 
Majority shareholders
Foreign Institutions
Domestic Funds
Held in 0 Schemes (0%)
Foreign Institutions
Held by 4 Foreign Institutions (0.0%)
Strategic Entities with highest holding
Highest Public shareholder
Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY
Jun'25
Jun'24
Change(%)
Net Sales
474,597.00
436,175.00
8.81%
Operating Profit (PBDIT) excl Other Income
113,754.00
81,912.00
38.87%
Interest
1,419.00
1,974.00
-28.12%
Exceptional Items
0.00
0.00
Consolidate Net Profit
85,500.00
85,383.00
0.14%
Operating Profit Margin (Excl OI)
202.20%
149.70%
5.25%
USD in Million.
Net Sales
YoY Growth in quarter ended Jun 2025 is 8.81% vs 24.32% in Jun 2024
Consolidated Net Profit
YoY Growth in quarter ended Jun 2025 is 0.14% vs 49.76% in Jun 2024
Annual Results Snapshot (Consolidated) - Mar'25
Mar'25
Mar'24
Change(%)
Net Sales
1,886,256.00
1,601,688.00
17.77%
Operating Profit (PBDIT) excl Other Income
377,392.00
250,235.00
50.82%
Interest
3,401.00
4,195.00
-18.93%
Exceptional Items
-1,490.00
5,062.00
-129.44%
Consolidate Net Profit
295,756.00
201,016.00
47.13%
Operating Profit Margin (Excl OI)
163.70%
116.10%
4.76%
USD in Million.
Net Sales
YoY Growth in year ended Mar 2025 is 17.77% vs 25.28% in Mar 2024
Consolidated Net Profit
YoY Growth in year ended Mar 2025 is 47.13% vs 84.10% in Mar 2024
About Daiichi Sankyo Co., Ltd. 
Daiichi Sankyo Co., Ltd.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






